March 1, 2003Journal of the American Society of Nephrology
Development of Renal Disease in People at High Cardiovascular Risk
Why the study?
Does ramipril prevent or delay the progression of albuminuria in patients at high cardiovascular risk with or without diabetes?
Population
7,674 participants with known vascular disease or diabetes plus one other cardiovascular risk factor…
Comparison
Ramipril vs Placebo
Design
RCT
Follow-up
4.5 years
Authors
Discussion
Loading...
Member takes
Implication
Supports ramipril to slow albuminuria progression in high CV risk patients; extends ACE inhibitor renoprotection to mixed diabetes status.
Structured PICO
Does ramipril prevent or delay the progression of albuminuria in patients at high cardiovascular risk with or without diabetes?
P
Population
7,674 participants with known vascular disease or diabetes plus one other cardiovascular risk factor, excluding those with heart failure, known impaired left ventricular function, dipstick-positive proteinuria (>1+), or serum creatinine >2.3 mg/dl, who had albuminuria data at baseline and follow-up.
I
Intervention
Ramipril
C
Comparator
Placebo
O
Outcome
Any progression of albuminuria (defined as new microalbuminuria or new clinical proteinuria) over 4.5 yearssurrogate
In patients at high cardiovascular risk with or without diabetes, ramipril significantly reduces or delays the progression of albuminuria.
Cite This Study
Mann et al. (2003) studied this question.